IMVT

Jay S. Stout

Known title: Chief Technology OfficerCIK: 0001702969

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.

this person other insiders at IMVT

Transaction History

IMVT▼ Sell$71K
IMVT▼ Sell$51K
IMVT▼ Sell$111K
IMVT▼ Sell$75K
IMVT▼ Sell$4K
IMVT▼ Sell$55K
IMVT▼ Sell$3K
IMVT▼ Sell$262K
IMVT▼ Sell$1.3M
IMVT▼ Sell$82K
IMVT▼ Sell$214K
IMVT▼ Sell$38K
IMVT▲ Buy$0
IMVT▼ Sell$51K
IMVT▼ Sell$30K
IMVT▼ Sell$1K
IMVT▼ Sell$48K
IMVT▼ Sell$26K
IMVT▼ Sell$51K
IMVT▼ Sell$26K
IMVT▼ Sell$28K
IMVT▼ Sell$65K
IMVT▲ Buy$0
IMVT▼ Sell$52K
IMVT▼ Sell$81K
IMVT▼ Sell$78K
IMVT▼ Sell$209K
IMVT▲ Buy$0
IMVT▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.